Reduced price! Gerovital View larger

Gerovital H3


Gerovital H3 injection

More details

20 Items

By buying this product you can collect up to 5 loyalty points. Your cart will total 5 points that can be converted into a voucher of USD1.00.




Add to wishlist

More info

Gerovital H3 injection

Gerovital H3 Injections immediate effects recommend it for the patients in need for faster, visible results.

The original Gerovital H3 
Injections formula by the Professor Doctor Ana Aslan is perfect and therefore it remained unaltered for the last 60 years due to its effectiveness.

The secret of its efficiency it is the balanced quantity of Procaine Hydrochloride contained in each and every Gerovital H3 injections vial as originally recommended by Ana Aslan
 plus the special stabilizing enhancers.

Pharmaceutical form:

Injectable solution intramuscular



One ampoule contains:

Procaine hydrochloride100 mg

Benzoic acid 6 mg

Disodium phosphate dodecahydrate.0.5 mg

Potassium metabisulfite.. 5 mg

Distilled water for injectable solutions up to 5 ml

Pharmacotherapeutic group:

Alimentary tract and metabolism. Tonic preparations.

ATC code: A13 AN01


Therapeutic indications:

Protection of the organism against aging phenomena. 

Depressive syndrome (light and moderate depression), in precocious stages, 

especially when conventional therapy is not well-tolerated or it has contraindications.

Parkinsonian syndromes where it can be used in monotherapy or associated 

with other antiparkinsonian drugs, especially with dopaminergic agents.

Osteoarthritis (chronic degenerative rheumatism)

Systemic arteriosclerosis with hypercholesterolemia, ischaemic heart disease, 

arthritis, cerebral atherosclerosis.



Hypersensitivity to procaine in antecedents or tested.

Severe arterial hypotension.

Associated treatment with sulfonamides (except the antidiabetic ones) and with

acetylcholinesterase agents: neostygmine, eserine (physostigmine) and pyridostigmine.


Precautions regarding medicinal product administration:

Before starting the treatment, a test for individual tolerance to procaine should be made (see

under Posology and method of administration).


The treatment must take place under medical supervision, mainly in the first series of treatment,

in order to establish the optimal dose.


The product should be administered with caution in patients with orthostatic hypotension.

Although procaine medication is not carcinogenic, it is not recommended to the patients with

cancer, as its stimulating effect on mitotic potential of the neoplasic cell is not excluded.

Interactions with other medicinal products or other substances:

Gerovital GH3 should not be administered simultaneously with sulphonamides (antagonistic

mechanism of action) except the antidiabetic ones, anticholinesterases: neostygmine, eserine

(physostigmine) and pyridostigmine.

Special warnings:

Pregnant and breast-feeding women:

The studies on animals did not show teratogenic effects. In absence of teratogenic effects on

animals, malformative effects on humans are not expected. However, the clinical experience

with Gerovital GH3 is mainly on patients over the procreation period. For these reasons we do not

recommend the use of the product during pregnancy and lactation.

Potential effect on the ability to drive or to use machines: 

The product does not interfere with these abilities. 

Posology and method of administration:

Before starting the treatment with Gerovital GH3 it is compulsory to test individual sensitivity to

procaine, as follows: 1 ml from the injectable solution of Gerovital GH3 will be administered

subcutaneously and after 24 hours the test should be repeated with 1.5 ml solution

intramuscularly. If any allergic reaction occurs, the treatment is not recommended.

For protection of the organism against aging phenomena (standard schedule), alternative

courses of injections and tablets of Gerovital GH3 should be administered, as follows:

Injectable solution: 1 intramuscular injection, 3 times a week (one ampoule every other day),

over a period of 4 weeks (12 ampoules).

Depressive syndrome:

1-st week: 1 ampoule i.m. /day, 3 times a week (i.e., on Monday, on Wednesday and on Friday);

2-nd and 3-rd week: 1 ampoules i.m., 3 times a week;

4 th week: 2 ampoules i.m., 3 times a week.

The treatment should be repeated 4-6 times a year.

Parkinsonian syndromes:

Daily administration of 1 ampoule i.m.  for 15 days.


1 ampoule i.m. / day, for 15-21 days and then 1 ampoule i.m. 3 times a week (every other day),

for 4 weeks, repeated of 4-5 times /year. 

Systemic arteriosclerosis:

Depending of the intensity and the localization of the process, the treatment should be as

follows: 1 ampoule i.m. / day, 3 times a week, 4 weeks (12 ampoules), repeated 5-6 times /year.

Adverse reactions, which can occur during the use of the medicinal product:

Administration of Gerovital GH3 may produce allergic reactions in patients with hypersensitivity

to procaine like skin rash or pruritus. These effects impose an immediate stop of the treatment.

Minor effects may occur especially at the beginning of the treatment like: dizziness, weakness

and palpitations. These effects can be avoided if after the injection the patient rests in bed for 10-

15 minutes.


There are no reports of overdose related to administration of Gerovital GH3. In case of accidentally injection of high doses, severe hypotension, convulsions, coma, respiratory arrest may occur.

The treatment is symptomatic and support of vital functions.


Store below 25.0 C.

Keep out of the reach of children.

Do not use after the expiry date printed on the package.


Primary package: brown ampoule of 5 ml

Secondary package: folding box with 5 brown ampoules of 5 ml

folding box with 10 brown ampoules of 5 ml


No customer comments for the moment.

Write a review

Gerovital H3

Gerovital H3

Gerovital H3 injection

Write a review